• 00:00 1.
    index 1
  • 00:23 2.
    Title
  • 01:40 3.
    About Breast Cancer
  • 03:16 4.
    Triple Negative Breast Cancer Subtype
  • 04:09 5.
    FUSCC TNBC Subtype
  • 05:16 6.
    FUSCC TNBC Subtype
  • 06:21 7.
    Luminal Androgen Receptor LAR
  • 07:22 8.
    Immunomodulatory IM
  • 08:09 9.
    Basal-like Immune-suppressed BLIS
  • 09:22 10.
    Mesenchymal-like MES
  • 10:13 11.
    FUTURE clinical trial
  • 11:02 12.
    Slide 12
  • 11:46 13.
    Metabolic Dysregulation in TNBCs
  • 13:25 14.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 14:20 15.
    Metabolic-Pathway-Based Stratification of TNBC
  • 15:30 16.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 16:51 17.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 17:23 18.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 18:28 19.
    Slide 20
  • 19:51 20.
    The Metabolomic Landscape of TNBC
  • 20:42 21.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 22:19 22.
    NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
  • 23:38 23.
    NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
  • 24:43 24.
    Slide 26
  • 25:18 25.
    Ferroptosis
  • 26:14 26.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 27:03 27.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 28:05 28.
    Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
  • 28:42 29.
    Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
  • 29:58 30.
    Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
  • 31:01 31.
    Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
  • 31:35 32.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 32:33 33.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 33:43 34.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 34:23 35.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 35:42 36.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 37:19 37.
    GPX4 Inhibitors Diminish Tumor Growth In Vivo
  • 38:38 38.
    Slide 40
  • 39:37 39.
    Slide 41
  • 40:31 40.
    Slide 40
  • 45:25 41.
    Polar Metabolite and Lipid Profiling of TNBC
  • 45:36 42.
    The Metabolomic Landscape of TNBC
  • 46:14 43.
    Metabolic-Pathway-Based Stratification of TNBC
  • 47:25 44.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 50:47 45.
    Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
  • 51:05 46.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 51:06 47.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 51:07 48.
    Ferroptosis
  • 51:07 49.
    Slide 26
  • 51:08 50.
    Ferroptosis
  • 55:36 51.
    About Breast Cancer
  • 56:13 52.
    ** after 1112seminar.pptx
  • 56:15 53.
    About Breast Cancer
  • 56:17 54.
    Triple Negative Breast Cancer Subtype
  • 56:18 55.
    FUSCC TNBC Subtype
  • 56:18 56.
    FUSCC TNBC Subtype
  • 56:19 57.
    Luminal Androgen Receptor LAR
  • 56:19 58.
    Immunomodulatory IM
  • 56:21 59.
    Basal-like Immune-suppressed BLIS
  • 56:22 60.
    Mesenchymal-like MES
  • 56:22 61.
    Basal-like Immune-suppressed BLIS
  • 56:23 62.
    Immunomodulatory IM
  • 56:26 63.
    Luminal Androgen Receptor LAR
  • 56:27 64.
    FUSCC TNBC Subtype
  • 56:27 65.
    Luminal Androgen Receptor LAR
  • 56:28 66.
    Immunomodulatory IM
  • 56:28 67.
    Basal-like Immune-suppressed BLIS
  • 56:29 68.
    Mesenchymal-like MES
  • 56:30 69.
    Basal-like Immune-suppressed BLIS
  • 56:30 70.
    Immunomodulatory IM
  • 56:31 71.
    Luminal Androgen Receptor LAR
  • 57:11 72.
    Immunomodulatory IM
  • 57:12 73.
    Basal-like Immune-suppressed BLIS
  • 57:12 74.
    Mesenchymal-like MES
  • 57:14 75.
    FUTURE clinical trial
  • 57:15 76.
    Slide 12
  • 57:16 77.
    Metabolic Dysregulation in TNBCs
  • 57:19 78.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 57:26 79.
    Metabolic Dysregulation in TNBCs
  • 57:30 80.
    About Breast Cancer
  • 58:17 81.
    Triple Negative Breast Cancer Subtype
  • 58:17 82.
    FUSCC TNBC Subtype
  • 58:41 83.
    FUSCC TNBC Subtype
  • 58:42 84.
    Luminal Androgen Receptor LAR
  • 58:42 85.
    Immunomodulatory IM
  • 58:43 86.
    Basal-like Immune-suppressed BLIS
  • 58:43 87.
    Mesenchymal-like MES
  • 58:44 88.
    FUTURE clinical trial
  • 1:00:55 89.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:01:02 90.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:01:04 91.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:01:11 92.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:01:15 93.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:03:45 94.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:03:48 95.
    The Metabolomic Landscape of TNBC
  • 1:04:45 96.
    Slide 20
  • 1:04:47 97.
    The Metabolomic Landscape of TNBC
  • 1:04:52 98.
    Slide 20
  • 1:04:54 99.
    Polar Metabolite and Lipid Profiling of TNBC
  • 1:05:21 100.
    The Metabolomic Landscape of TNBC
  • 1:05:23 101.
    Polar Metabolite and Lipid Profiling of TNBC
  • 1:05:23 102.
    The Metabolomic Landscape of TNBC
  • 1:05:24 103.
    Polar Metabolite and Lipid Profiling of TNBC
  • 1:05:32 104.
    The Metabolomic Landscape of TNBC
  • 1:05:33 105.
    Polar Metabolite and Lipid Profiling of TNBC
  • 1:05:39 106.
    The Metabolomic Landscape of TNBC
  • 1:05:48 107.
    Polar Metabolite and Lipid Profiling of TNBC
  • 1:05:49 108.
    Slide 20
  • 1:05:50 109.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:05:50 110.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:05:51 111.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:05:52 112.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:06:08 113.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 1:06:17 114.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:06:44 115.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 1:06:44 116.
    Metabolic Dysregulation in TNBCs
  • 1:06:45 117.
    Slide 12
  • 1:06:46 118.
    FUTURE clinical trial
  • 1:06:46 119.
    Slide 12
  • 1:07:03 120.
    Metabolic Dysregulation in TNBCs
  • 1:07:04 121.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 1:07:04 122.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:08:04 123.
    NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
  • 1:09:47 124.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 1:09:54 125.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 1:09:56 126.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 1:10:11 127.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 1:10:12 128.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 1:10:12 129.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 1:12:11 130.
    Slide 40
  • 1:13:17 131.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 1:15:14 132.
    FUSCC TNBC Subtype
  • 1:15:22 133.
    Luminal Androgen Receptor LAR
  • 1:15:23 134.
    Immunomodulatory IM
  • 1:15:24 135.
    Basal-like Immune-suppressed BLIS
  • 1:15:25 136.
    Mesenchymal-like MES
  • 1:15:26 137.
    FUTURE clinical trial
  • 1:15:55 138.
    Mesenchymal-like MES
  • 1:15:55 139.
    Basal-like Immune-suppressed BLIS
  • 1:15:56 140.
    Immunomodulatory IM
  • 1:15:56 141.
    Luminal Androgen Receptor LAR
  • 1:15:57 142.
    FUSCC TNBC Subtype
  • 1:15:57 143.
    FUSCC TNBC Subtype
  • 1:15:58 144.
    Triple Negative Breast Cancer Subtype
  • 1:15:59 145.
    About Breast Cancer
  • 1:16:00 146.
    Title
  • 1:16:18 147.
    About Breast Cancer
  • 1:16:28 148.
    Triple Negative Breast Cancer Subtype
  • 1:16:29 149.
    FUSCC TNBC Subtype
  • 1:16:32 150.
    Triple Negative Breast Cancer Subtype
  • 1:17:20 151.
    FUSCC TNBC Subtype
  • 1:18:16 152.
    FUSCC TNBC Subtype
  • 1:18:44 153.
    Luminal Androgen Receptor LAR
  • 1:19:09 154.
    Immunomodulatory IM
  • 1:19:09 155.
    Basal-like Immune-suppressed BLIS
  • 1:19:46 156.
    Mesenchymal-like MES
  • 1:20:09 157.
    FUTURE clinical trial
  • 1:20:28 158.
    Slide 12
  • 1:21:03 159.
    Metabolic Dysregulation in TNBCs
  • 1:21:04 160.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 1:21:04 161.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:21:36 162.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:21:37 163.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:21:38 164.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:22:08 165.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:22:09 166.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:22:16 167.
    Slide 20
  • 1:22:36 168.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:22:37 169.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:22:38 170.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:22:39 171.
    Metabolic-Pathway-Based Stratification of TNBC
  • 1:22:39 172.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:24:25 173.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:24:27 174.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 1:24:32 175.
    Slide 26
  • 1:24:37 176.
    Ferroptosis
  • 1:25:19 177.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 1:25:52 178.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 1:25:53 179.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 1:25:53 180.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 1:27:20 181.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 1:28:13 182.
    GPX4 Inhibitors Diminish Tumor Growth In Vivo
  • 1:34:00 183.
    ** after 1112seminar.pptx
  • 索引
  • 筆記
  • 討論
  • 全螢幕
20230220 lab meeting_家銘 (no sound)
長度: 1:34:08, 瀏覽: 269, 最近修訂: 2023-05-16
    上一篇 下一篇
    • 00:00 1.
      index 1
    • 00:23 2.
      Title
    • 01:40 3.
      About Breast Cancer
    • 03:16 4.
      Triple Negative Breast Cancer Subtype
    • 04:09 5.
      FUSCC TNBC Subtype
    • 05:16 6.
      FUSCC TNBC Subtype
    • 06:21 7.
      Luminal Androgen Receptor LAR
    • 07:22 8.
      Immunomodulatory IM
    • 08:09 9.
      Basal-like Immune-suppressed BLIS
    • 09:22 10.
      Mesenchymal-like MES
    • 10:13 11.
      FUTURE clinical trial
    • 11:02 12.
      Slide 12
    • 11:46 13.
      Metabolic Dysregulation in TNBCs
    • 13:25 14.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 14:20 15.
      Metabolic-Pathway-Based Stratification of TNBC
    • 15:30 16.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 16:51 17.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 17:23 18.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 18:28 19.
      Slide 20
    • 19:51 20.
      The Metabolomic Landscape of TNBC
    • 20:42 21.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 22:19 22.
      NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
    • 23:38 23.
      NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
    • 24:43 24.
      Slide 26
    • 25:18 25.
      Ferroptosis
    • 26:14 26.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 27:03 27.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 28:05 28.
      Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
    • 28:42 29.
      Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
    • 29:58 30.
      Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
    • 31:01 31.
      Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
    • 31:35 32.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 32:33 33.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 33:43 34.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 34:23 35.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 35:42 36.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 37:19 37.
      GPX4 Inhibitors Diminish Tumor Growth In Vivo
    • 38:38 38.
      Slide 40
    • 39:37 39.
      Slide 41
    • 40:31 40.
      Slide 40
    • 45:25 41.
      Polar Metabolite and Lipid Profiling of TNBC
    • 45:36 42.
      The Metabolomic Landscape of TNBC
    • 46:14 43.
      Metabolic-Pathway-Based Stratification of TNBC
    • 47:25 44.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 50:47 45.
      Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
    • 51:05 46.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 51:06 47.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 51:07 48.
      Ferroptosis
    • 51:07 49.
      Slide 26
    • 51:08 50.
      Ferroptosis
    • 55:36 51.
      About Breast Cancer
    • 56:13 52.
      ** after 1112seminar.pptx
    • 56:15 53.
      About Breast Cancer
    • 56:17 54.
      Triple Negative Breast Cancer Subtype
    • 56:18 55.
      FUSCC TNBC Subtype
    • 56:18 56.
      FUSCC TNBC Subtype
    • 56:19 57.
      Luminal Androgen Receptor LAR
    • 56:19 58.
      Immunomodulatory IM
    • 56:21 59.
      Basal-like Immune-suppressed BLIS
    • 56:22 60.
      Mesenchymal-like MES
    • 56:22 61.
      Basal-like Immune-suppressed BLIS
    • 56:23 62.
      Immunomodulatory IM
    • 56:26 63.
      Luminal Androgen Receptor LAR
    • 56:27 64.
      FUSCC TNBC Subtype
    • 56:27 65.
      Luminal Androgen Receptor LAR
    • 56:28 66.
      Immunomodulatory IM
    • 56:28 67.
      Basal-like Immune-suppressed BLIS
    • 56:29 68.
      Mesenchymal-like MES
    • 56:30 69.
      Basal-like Immune-suppressed BLIS
    • 56:30 70.
      Immunomodulatory IM
    • 56:31 71.
      Luminal Androgen Receptor LAR
    • 57:11 72.
      Immunomodulatory IM
    • 57:12 73.
      Basal-like Immune-suppressed BLIS
    • 57:12 74.
      Mesenchymal-like MES
    • 57:14 75.
      FUTURE clinical trial
    • 57:15 76.
      Slide 12
    • 57:16 77.
      Metabolic Dysregulation in TNBCs
    • 57:19 78.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 57:26 79.
      Metabolic Dysregulation in TNBCs
    • 57:30 80.
      About Breast Cancer
    • 58:17 81.
      Triple Negative Breast Cancer Subtype
    • 58:17 82.
      FUSCC TNBC Subtype
    • 58:41 83.
      FUSCC TNBC Subtype
    • 58:42 84.
      Luminal Androgen Receptor LAR
    • 58:42 85.
      Immunomodulatory IM
    • 58:43 86.
      Basal-like Immune-suppressed BLIS
    • 58:43 87.
      Mesenchymal-like MES
    • 58:44 88.
      FUTURE clinical trial
    • 1:00:55 89.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:01:02 90.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:01:04 91.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:01:11 92.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:01:15 93.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:03:45 94.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:03:48 95.
      The Metabolomic Landscape of TNBC
    • 1:04:45 96.
      Slide 20
    • 1:04:47 97.
      The Metabolomic Landscape of TNBC
    • 1:04:52 98.
      Slide 20
    • 1:04:54 99.
      Polar Metabolite and Lipid Profiling of TNBC
    • 1:05:21 100.
      The Metabolomic Landscape of TNBC
    • 1:05:23 101.
      Polar Metabolite and Lipid Profiling of TNBC
    • 1:05:23 102.
      The Metabolomic Landscape of TNBC
    • 1:05:24 103.
      Polar Metabolite and Lipid Profiling of TNBC
    • 1:05:32 104.
      The Metabolomic Landscape of TNBC
    • 1:05:33 105.
      Polar Metabolite and Lipid Profiling of TNBC
    • 1:05:39 106.
      The Metabolomic Landscape of TNBC
    • 1:05:48 107.
      Polar Metabolite and Lipid Profiling of TNBC
    • 1:05:49 108.
      Slide 20
    • 1:05:50 109.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:05:50 110.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:05:51 111.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:05:52 112.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:06:08 113.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 1:06:17 114.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:06:44 115.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 1:06:44 116.
      Metabolic Dysregulation in TNBCs
    • 1:06:45 117.
      Slide 12
    • 1:06:46 118.
      FUTURE clinical trial
    • 1:06:46 119.
      Slide 12
    • 1:07:03 120.
      Metabolic Dysregulation in TNBCs
    • 1:07:04 121.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 1:07:04 122.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:08:04 123.
      NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
    • 1:09:47 124.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 1:09:54 125.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 1:09:56 126.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 1:10:11 127.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 1:10:12 128.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 1:10:12 129.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 1:12:11 130.
      Slide 40
    • 1:13:17 131.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 1:15:14 132.
      FUSCC TNBC Subtype
    • 1:15:22 133.
      Luminal Androgen Receptor LAR
    • 1:15:23 134.
      Immunomodulatory IM
    • 1:15:24 135.
      Basal-like Immune-suppressed BLIS
    • 1:15:25 136.
      Mesenchymal-like MES
    • 1:15:26 137.
      FUTURE clinical trial
    • 1:15:55 138.
      Mesenchymal-like MES
    • 1:15:55 139.
      Basal-like Immune-suppressed BLIS
    • 1:15:56 140.
      Immunomodulatory IM
    • 1:15:56 141.
      Luminal Androgen Receptor LAR
    • 1:15:57 142.
      FUSCC TNBC Subtype
    • 1:15:57 143.
      FUSCC TNBC Subtype
    • 1:15:58 144.
      Triple Negative Breast Cancer Subtype
    • 1:15:59 145.
      About Breast Cancer
    • 1:16:00 146.
      Title
    • 1:16:18 147.
      About Breast Cancer
    • 1:16:28 148.
      Triple Negative Breast Cancer Subtype
    • 1:16:29 149.
      FUSCC TNBC Subtype
    • 1:16:32 150.
      Triple Negative Breast Cancer Subtype
    • 1:17:20 151.
      FUSCC TNBC Subtype
    • 1:18:16 152.
      FUSCC TNBC Subtype
    • 1:18:44 153.
      Luminal Androgen Receptor LAR
    • 1:19:09 154.
      Immunomodulatory IM
    • 1:19:09 155.
      Basal-like Immune-suppressed BLIS
    • 1:19:46 156.
      Mesenchymal-like MES
    • 1:20:09 157.
      FUTURE clinical trial
    • 1:20:28 158.
      Slide 12
    • 1:21:03 159.
      Metabolic Dysregulation in TNBCs
    • 1:21:04 160.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 1:21:04 161.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:21:36 162.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:21:37 163.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:21:38 164.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:22:08 165.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:22:09 166.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:22:16 167.
      Slide 20
    • 1:22:36 168.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:22:37 169.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:22:38 170.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:22:39 171.
      Metabolic-Pathway-Based Stratification of TNBC
    • 1:22:39 172.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:24:25 173.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:24:27 174.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 1:24:32 175.
      Slide 26
    • 1:24:37 176.
      Ferroptosis
    • 1:25:19 177.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 1:25:52 178.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 1:25:53 179.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 1:25:53 180.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 1:27:20 181.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 1:28:13 182.
      GPX4 Inhibitors Diminish Tumor Growth In Vivo
    • 1:34:00 183.
      ** after 1112seminar.pptx
    位置
    1. 知識庫
    2. ...
    3. 2023
    資料夾名稱
    2023
    發表人
    黃照穎
    單位
    賴亮全教授
    建立
    2023-04-17 09:01:51
    最近修訂
    2023-05-16 16:29:40
    長度
    1:34:08

    臺北市仁愛路一段1號10樓1009室

    R1009 10F No1 Sec1 Ren-Ai Rd, Taipei 100233, Taiwan.

    E-mail: llai@ntu.edu.tw

    Tel: 886-2-2312-3456 # 288241

    Lab: 886-2-2393-8235